Clinical Trials Logo

Myeloid Leukemia clinical trials

View clinical trials related to Myeloid Leukemia.

Filter by:

NCT ID: NCT06235801 Not yet recruiting - Myeloid Leukemia Clinical Trials

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Start date: July 31, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

To learn the recommended dose of momelotinib that can be given in combination with gilteritinib to participants with AML.

NCT ID: NCT06130579 Recruiting - Clinical trials for Myelodysplastic Syndromes

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation. To explore the efficacy of interferon-α in reducing the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

NCT ID: NCT05871008 Recruiting - Breast Cancer Clinical Trials

Integrated Actionable Aging Assessment for Cancer Patients Pilot

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

Aging is the greatest risk factor for cancer incidence and mortality. Geriatric screening is recommended to help with treatment discussions, inform intensity of treatment, and identify supportive care needs. Despite a strong evidence base, geriatric assessments are not implemented routinely in oncologic clinics. Similarly, important information on social determinants of health, mental health, and health behaviors are inconsistently assessed, and almost never in an integrated fashion. In an effort to support clinicians delivering the recommended goal-concordant care, the investigators will integrate assessment of geriatric issues, health behaviors, mental health, and social determinants of health into an efficient, actionable contextual assessment system for older cancer patients called Integrated Aging Assessment for Action for Cancer Patients (IA3-CP). The investigators will use D&I strategies including co-creation engagement approaches and form-function methods to develop workflow processes that feasibly integrate the IA3-CP into usual initial assessment with the oncology team. Our objective is to develop and conduct a randomized pilot of the IA3-CP system and hypothesize that our results will show it can be implemented consistently, acted on, improve quality of care, and enhance patient-provider interactions.

NCT ID: NCT05787951 Not yet recruiting - Myeloid Leukemia Clinical Trials

Frequency and Risk Factors of Acute Myeloid Leukemia

Start date: May 1, 2023
Phase:
Study type: Observational

1. to assess the frequency of acute myeloid leukemia at clinical Haematology unit of Assiute university hospital 2. to study correlations of known risk factors and if there are new risk factors participate in increasing frequency of acute myeloid leukemia

NCT ID: NCT05363488 Completed - Myeloid Leukemia Clinical Trials

Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland

Start date: October 8, 2021
Phase:
Study type: Observational

This study will describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia (CML) used in a real world clinical practice setting.

NCT ID: NCT05309018 Not yet recruiting - Myeloid Leukemia Clinical Trials

Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML

LAMIPA
Start date: July 15, 2024
Phase:
Study type: Observational

Advanced Practice Nurse (APN) is a new contributor in the French healthcare system. APN is part of a multidisciplinary team and aim to monitor patients under the coordination of the doctor particularly in onco-hematology. The aim of the study is to describe the different perceptions and expectations of APN monitoring according to patients with acute myeloid leukemia (AML) and their care team. This study will involve 10 patients, recruited over a provisional period of 5 months and 25 member of care team. Patients and their care team will be asked about their perceptions and expectations of APN participation in (AML monitoring) during a semi-structured interviews.

NCT ID: NCT05035706 Recruiting - Clinical trials for Acute Myeloid Leukemia

Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors

Start date: June 30, 2021
Phase: Early Phase 1
Study type: Interventional

This clinical trial assesses how the immune system responds to leukemia tumors after low dose radiation delivered as part of standard of care. The information learned in this study may help them know if adding immunotherapy (a type of treatment that uses the immune system to fight cancer) can be helpful in future leukemia patients receiving radiation.

NCT ID: NCT05031897 Recruiting - Clinical trials for Acute Myeloid Leukemia

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant

Start date: October 25, 2021
Phase: Phase 2
Study type: Interventional

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other forms of treatment. In recent years, less intense conditioning regimens with radiation and chemotherapy prior to HSCT have been developed. Radiation therapy uses high energy sources to kill cancer cells and shrink tumors while chemotherapy drugs like fludarabine and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study evaluates whether a two-step approach with lower-intensity regimens of these treatments prior to HSCT reduces the rate of TRM.

NCT ID: NCT04714372 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

Start date: November 3, 2021
Phase: Phase 1
Study type: Interventional

This Phase I open-label dose escalation study is conducted in two stages with a primary endpoint to identify the maximum tolerated dose (MTD) of FT538 when administered with daratumumab in patients 12 years and older with advanced acute myeloid leukemia (AML) and related myeloid diseases.

NCT ID: NCT04628338 Completed - Clinical trials for Myelodysplastic Syndromes

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Start date: March 8, 2021
Phase: Early Phase 1
Study type: Interventional

This study proposes a safe dosing regimen IFN-γ that is sufficient to stimulate IFN-γ receptors on malignant blasts in patients who developed relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after alloSCT with no active or history of III-IV acute graft-versus-host disease (GVHD). It is hypothesized that IFN-γ will promote graft-vs-leukemia (GVL) in patients with AML/MDS that has relapsed after alloSCT.